Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector
A PHASE 1 RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, 3-TREATMENT CROSS-OVER STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF INTRAMUSCULAR INJECTION OF NALOXONE HCL 5 Milligrams (mg) [5mg/0.5 Milliliters (mL] USING A QUICKSHOT™ AUTOINJECTOR COMPARED TO 2 mg NALOXONE INTRAMUSCULAR INJECTION AND 2 mg NALOXONE INTRAVENOUS INJECTION IN HEALTHY ADULT PARTICIPANTS
調査の概要
状態
条件
詳細な説明
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06511
- New Haven Clinical Research Unit
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
Healthy male and/or female participants of non-childbearing potential, who, at the time of screening, are between the ages of 18 and 55 years, inclusive.
Refer to protocol for reproductive criteria for male and female participants.
Type of Participant and Disease Characteristics:
- Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, 12-lead ECG, and/or clinical laboratory tests.
Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
Weight:
- BMI of 17.5 to 30.5 kg/m2; and a total body weight > 50 kg (110 lb).
Informed Consent:
5. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
-
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Current or past diagnosis of any type of drug dependence within the past year will not be eligible to participate. History of alcohol abuse, dependence or binge drinking and/or any other illicit drug use within 6 months of screening. Binge drinking is hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
- If fever is present within 7 days of admission or screening.
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- History of HIV infection, hepatitis B, or hepatitis C, positive testing for HIV, HBsAg, or HCVAb. Hepatitis B vaccination is allowed.
Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Prior/Concomitant Therapy:
- Use of prescription or nonprescription drugs and dietary and herbal supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention. Prior/Concurrent Clinical Study Experience:
Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
Diagnostic Assessments:
- A positive urine drug test.
- Has participated in, is currently participating in, or is seeking treatment for substance-and/or alcohol-related disorders (excluding nicotine and caffeine).
- Has a positive alcohol breathalyzer test at screening or upon admission to the study center of Treatment Period. Positive results may be repeated and/or participants re-scheduled at the investigator's discretions.
- Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility. Repeated BP tests should be spaced at least 5 minutes apart.
- Screening supine 12-lead ECG demonstrating a QTc interval > 450 msec or a QRS interval > 120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility.
Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary:
Abnormal platelet count and/or PT/INR; AST or ALT level ≥1.5 × ULN; Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.
Other Exclusions:
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
- History of hypersensitivity to naloxone or any of the components in the formulation of the study products.
Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
-
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:naloxone 5 mg IM autoinjector
participants will receive in random order, a single naloxone 5 mg IM autoinjector injection into the lateral thigh
|
5 mg (5 mg/0.5 mL) IM autoinjector injection into lateral thigh
|
アクティブコンパレータ:naloxone 2 mg IM
participants will receive in random order, a single naloxone 2 mg IM injection into the gluteus muscle
|
2 mg IM (2mg/2 mL) injection into gluteal muscle
2 mg bolus IV (2mg/2 mL)
|
アクティブコンパレータ:naloxone 2mg bolus IV
participants will receive in random order, a single naloxone 2 mg bolus IV injection
|
2 mg IM (2mg/2 mL) injection into gluteal muscle
2 mg bolus IV (2mg/2 mL)
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Maximum observed plasma naloxone concentration (Cmax) of a single 5 mg IM autoinjector injection compared to a 2 mg IM injection
時間枠:predose, 2.5, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480, and 1440 minutes after dose
|
Comparison of bioavailability
|
predose, 2.5, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480, and 1440 minutes after dose
|
Area under the naloxone concentration versus time curve (AUC) from time zero to the last collection time (AUClast) of a single 5 mg IM autoinjector injection compared to a 2 mg IM injection
時間枠:predose, 2.5, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480, and 1440 minutes after dose
|
Comparison of bioavailability
|
predose, 2.5, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480, and 1440 minutes after dose
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
AUC from time zero to 2.5 minutes (AUC0-2.5)
時間枠:predose and 2.5 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose and 2.5 minutes after dose
|
AUC from time zero to 5 minutes (AUC0-5)
時間枠:predose, 2.5 and 5 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5 and 5 minutes after dose
|
AUC from time zero to 15 minutes (AUC0-15)
時間枠:predose, 2.5, 5, 10 and 15 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5, 5, 10 and 15 minutes after dose
|
AUC from time zero to 30 minutes (AUC0-30)
時間枠:predose, 2.5, 5, 10, 15, and 30 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5, 5, 10, 15, and 30 minutes after dose
|
AUC from time zero extrapolated to infinity (AUCinf) [if data permit]
時間枠:predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Time to maximum observed naloxone plasma concentration (Tmax) [if data permit],
時間枠:predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Time for naloxone plasma concentration to decrease by one half (t1/2) [if data permit].
時間枠:predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Number of participants with a clinically significant change from baseline physical examination
時間枠:baseline to 28 days after last dose
|
Safety and tolerability all treatments
|
baseline to 28 days after last dose
|
Number of participants with a clinically significant change from baseline vital signs
時間枠:baseline to 28 days after last dose
|
Safety and tolerability all treatments
|
baseline to 28 days after last dose
|
Number of participants with a clinically significant change from baseline clinical safety laboratory measurements
時間枠:baseline to 28 days after last dose
|
Safety and tolerability all treatment arms
|
baseline to 28 days after last dose
|
Number of participants with clinically significant AEs from baseline
時間枠:baseline to 28 days after last dose
|
Safety and tolerability all treatment arms
|
baseline to 28 days after last dose
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- C2431001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
NaxRedy ™の臨床試験
-
Asklepios Kliniken Hamburg GmbHUniversity of Kiel完了気道管理 | ラリンジアル マスク エアウェイ | 光ファイバー挿管
-
Medtronic CardiovascularMedtronic完了
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive Medicalわからない脳損傷、慢性 | Cerebellar Cognitive Affective Syndrome | 小脳無言症
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive Medicalわからない側頭葉てんかん
-
Boston Scientific Corporation完了一過性脳虚血発作 | 血栓塞栓性脳卒中 | 脳卒中予防アメリカ, アルゼンチン, ドイツ
-
Medtronic Cardiovascular積極的、募集していない大動脈瘤ドイツ, ニュージーランド, アメリカ, オランダ, スイス, イギリス, スペイン, オーストラリア, イタリア, スウェーデン, フランス, オーストリア, スロバキア
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting, Inc.募集